イノベーションハブ
/
ブログ
/
Leveraging Big Data to Transform Target Selection and Drug Discovery

Leveraging Big Data to Transform Target Selection and Drug Discovery

In 2013, the European Bioinformatics Institute hosted 15 petabytes data in their shared file systems. This increased to 25 petabytes in 2014, which...

Sean Preci

公開日

February 17, 2016

In 2013, the European Bioinformatics Institute hosted 15 petabytes data in their shared file systems. 1 This increased to 25 petabytes in 2014, which is equal to the hard drive space of over 12,000 current-day typical personal laptops (each with a 2 terabyte drive).

Abstract molecular cluster with three connected blue-green spheres on a white background.

次のステップへ進む

Explore Suppliers

関連する専門知識を持つ信頼できるパートナーを探す

Review Capabilities

サービス、経験、実績を比較する

Start Your Project

つながり、協業を始める

Browse Suppliers

Post a Project

How It Works

執筆者

Sean Preci

この記事をシェアする

トピック

Disease Models

Pharmacology

ニュースレターに登録する

最新のニュースやイノベーション情報をメールで直接受け取ることができます。ぜひご登録ください。

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Topics of Interest

Biology
Biometrics
Chemical & Compound Analysis
Chemistry, Manufacturing & Controls
Clinical Trials
Discovery Chemistry
DMPK
Health Economics & Outcomes Research (HEOR)
Human Biological Samples (HBS)
Market Access
Non-Human Biological Samples (NHBS)
Pharmacology
Raw Materials
Real-World Data (RWD)
Real-World Evidence (RWE)
Safety & Pharmacovigilance
Toxicology
Medical Communications

Email address

I would like to receive the monthly Scientist.com newsletter.

I agree to receive email communication from Scientist.com and accept the data privacy statement.

By submitting your information, you agree to our Terms of Service and Privacy Policy. You can opt out anytime.

ニュースレターに登録する

最新のニュースやイノベーション情報をメールで直接受け取ることができます。ぜひご登録ください。

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Topics of Interest

Biology
Biometrics
Chemical & Compound Analysis
Chemistry, Manufacturing & Controls
Clinical Trials
Discovery Chemistry
DMPK
Health Economics & Outcomes Research (HEOR)
Human Biological Samples (HBS)
Market Access
Non-Human Biological Samples (NHBS)
Pharmacology
Raw Materials
Real-World Data (RWD)
Real-World Evidence (RWE)
Safety & Pharmacovigilance
Toxicology
Medical Communications

Email address

I would like to receive the monthly Scientist.com newsletter.

I agree to receive email communication from Scientist.com and accept the data privacy statement.

By submitting your information, you agree to our Terms of Service and Privacy Policy. You can opt out anytime.

Leveraging Big Data to Transform Target Selection and Drug Discovery

次のステップへ進む

Explore Suppliers

Review Capabilities

Start Your Project

ニュースレターに登録する

ニュースレターに登録する

続きを読む

Building IND-enabled preclinical packages: Accelerating radiopharmaceutical development through integrated translational science

Ignyte Bio's Antigen-Specific T cells in NAM

What AI Finds in Clinical Notes About Myasthenia Gravis That Claims Data Misses

In Vivo Study: From Study Design, Execution to Pathology Assessment in One Laboratory at APS

The AI-Native Drug Discovery Program of the Future

From San Diego to Switzerland: Revisiting Scientist.com’s Vendor Discovery Days in 2026

What to Know About AAV Quality Before the Experiment Begins

Immortalized vs. Primary Cells: Choosing the Right Model for Your Research

AI Isn’t Replacing the Scientific Method. It’s Accelerating It.

Connecting Discovery: How Integrated Infrastructure Supports Better Decisions

What Experimental Data Do AI-Designed Antibodies Need?

From Vague Claims to Strict Compliance: The Global Regulatory Crackdown on Greenwashing

The Evolving Landscape of Drug Discovery for Metabolic Diseases

Regulatory Evolution in Substantial Evidence: The FDA’s One-Trial Pathway and the Strategic Implications for Biopharmaceutical Development

Accelerating the Design–Build–Test–Learn Cycle for AI-Driven Antibody Discovery

Screening the Unscreenable: How Physics-Grounded AI Is Expanding the Reach of Drug Discovery

Reducing risk in CRO studies: Choosing the right cell models for outsourced research

Cutting Months Off AAV Programs: The Synthetic DNA Shift

Speed Matters: Why RWE Acceleration Starts Upstream with Reusable Data

Making Sustainability More "Sustainable": Driving Transformation at Scale within Biopharma

Comprehensive Plasma cell-free RNA Profiling for Superior Cancer Detection

Advanced Screening Strategies for Molecular Glue Discovery

Why Large CROs and CDMOs Should Embrace Research Orchestration Platforms - Even with Existing Pharma Clients

AI in HEOR: Three Ways Artificial Intelligence Is Accelerating Evidence Generation

Supplier Spotlight: RadMD Imaging

AI Is Expanding What's Possible in Drug Discovery. Operational Friction Still Determines How Fast It Happens.

The Science of the "Gut Feeling": Why Techs are a Lab's Best Diagnostic Tool

Supplier Spotlight: MedChemExpress

HealthEconomics.com 2026 Pulse Check – March

Cell Line-Derived Xenografts: A Reliable Platform for Preclinical Cancer Drug Testing

続きを読む

Building IND-enabled preclinical packages: Accelerating radiopharmaceutical development through integrated translational science

Ignyte Bio's Antigen-Specific T cells in NAM

The AI-Native Drug Discovery Program of the Future

In Vivo Study: From Study Design, Execution to Pathology Assessment in One Laboratory at APS

現代のライフサイエンスを支えるデジタル基盤